Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
复制标题
下一代测序揭示的前列腺癌的分子病理学：基于基因组的个性化治疗的机会。
DOI：
10.1097/mou.0b013e32835e9ef4
复制
发表时间：
2013-05
影响因子：
2.5
通讯作者：
Sun Y
中科院分区：
文献类型：
--
作者：
Huang J;Wang JK;Sun Y
本文综述了最近发现的前列腺癌基因组突变。先进的测序技术使获得大量癌症基因组和转录组数据成为可能。这些技术已被用于对不同阶段的前列腺癌进行测序，从未经治疗的癌症到晚期去势抵抗性癌症，再到侵袭性小细胞神经内分泌癌。对于每一类前列腺癌，发现了不同和重叠的DNA序列改变，包括点突变，小插入或缺失，拷贝数变化和染色体重排。从低风险到高风险再到晚期癌症，基因组变异似乎逐步增加。这些新的发现大大增加了我们对人类前列腺癌遗传基础以及疾病进展和治疗抵抗的分子机制的了解。有些病变是潜在的治疗靶点。沿着这一方向的研究最终将使为个体患者设计个性化的管理计划成为可能。
This article reviews recently identified genomic mutations in prostate cancer. Advanced sequencing technologies have made it possible to obtain large amounts of data on genomes and transcriptomes of cancers. Such technologies have been used to sequence prostate cancer of different stages, from treatment-naive cancers, to advanced, castration-resistant cancers to the aggressive small cell neuroendocrine carcinomas. For each category of prostate cancer, distinct and overlapping DNA sequence alterations were discovered, including point mutations, small insertions or deletions, copy number changes and chromosomal rearrangements. There appears to be a stepwise increase in genomic alterations from low risk to high risk to advanced cancers. These novel findings have significantly increased our knowledge of the genetic basis of human prostate cancer and the molecular mechanisms responsible for disease progression and treatment resistance. Some of the lesions are potential therapeutic targets. Studies along this direction will eventually make it possible to design personalized management plans for individual patients.